OncoSpherix News & Events
OncoSpherix to Present Data from its Hypoxia Inducible Factor (HIF) Inhibitor 64B in Uveal Melanoma
April 12, 2023 64B is a small molecule therapeutic that inhibits the function of hypoxia inducible factors (HIFs) 64B given systemically inhibits primary tumor growth and metastases 64B was far superior to either sunitinib or selumetinib at causing a regression in...
OncoSpherix CEO to Serve as Keynote Speaker at 5th Meridian Drug Discovery Conference in Boston on Tuesday, November 8, 2022
The 5th Meridian Drug Discovery Conference will be held at the Embassy Suites by Hilton at Boston Longan Airport on November 7-8, 2022. Dr. Margaret Offermann will present a keynote address entitled "Mechanism Matters: Overcoming Past Failures in Developing HIF...
OncoSpherix’s CEO Will Give Keynote Presentation Entitled “Overcoming Past Challenges in Developing Safe and Effective Small Molecule Hypoxia Inducible Factor (HIF) Inhibitors for Treatment Of Aggressive Cancers” in San Francisco on Thursday, October 27
The Agile Falcon Drug Discovery Strategic Summit will be held at the Grand Hyatt at the San Francisco Airport on October 27-28, 2022. OncoSpherix's CEO, Dr. Margaret Offermann, will be presenting a keynote address entitled "Overcoming Past Challenges in Developing...
OncoSpherix’s CEO is Keynote Speaker and Moderator at Global Women in STEM Leadership Summit In Atlanta on June 6-7, 2022
The Global Women in STEM Leadership Summit is designed to inspire attendees through sessions tailored specifically for promoting women in STEM. It brings together influential leaders and founders from industry, academia, nonprofit and government to share their...
Serial Entrepreneur and Biotech Leader Thomas Saylor Joins Business Advisory Board of OncoSpherix
OncoSpherix is pleased to announce that Thomas Saylor has joined the company’s business advisory board. Mr. Saylor has served as CEO of six emerging biotech companies in the U.S., Europe and Asia, leading enterprises that cover drug development, pharmaceutical...
Internationally Renowned Medical Oncologist Dr. Harvey Golomb Joins Clinical Advisory Board of OncoSpherix
OncoSpherix is pleased to announce that Dr. Harvey Golomb has joined the Clinical Advisory Board of OncoSpherix. Dr. Golomb’s recognition as a preeminent leader in oncology began early in his career, as reflected by his election in 1990 as President of the American...
OncoSpherix’s Chief Scientific Officer Dr. Erwin Van Meir Honored with Endowed Professorship for Brain Cancer Research
Dr. Erwin Van Meir is the inaugural David Hart White Endowed Professorship for Brain Cancer Research at the National Cancer Institute-designated O’Neal Comprehensive Cancer Center at the University of Alabama Birmingham. Dr. Van Meir’s research illuminates how genetic...
OncoSpherix’s CEO will Give Keynote Address at Drug Discovery Nexus East Coast 2022 on April 21, 2022
Dr. Margaret K Offermann will be speaking on Thursday, April 21, 2022 from 11:30 AM -12:00 PM Eastern time at the Drug Discovery Nexus East Coast 2022 conference that will be held virtually. The title of her presentation is "Improving Design and Interpretation of...
Oncospherix’s Chief Scientific Officer Dr. Erwin Van Meir Publishes Study that Sheds Light on HIF-Regulated Genes that Contribute to Tumor Invasion and Metastasis in Eye Melanoma
Dr. Erwin Van Meir and colleagues published a study identifying HIF-regulated genes (P4HA1 and P4HA2) that contribute to the invasion of uveal melanoma cells into surrounding tissues. Importantly, this process could be blocked using a HIF inhibitor, KCN1, that works...
OncoSpherix’s Founding Scientist and Board of Directors’ member Binghe Wang, PhD, is Honored by his Selection as a National Academy of Inventors Fellow
OncoSpherix is pleased to announce that Dr. Binghe Wang has been elected as a fellow at the National Academy of Inventors. Dr. Wang is a renowned synthetic medicinal chemist with expertise in drug design, delivery, and molecular recognition. He is a founding scientist...